Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.51 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313516 | 1.00 | CTSK (0.51) | CTSKCTSSTDP1ALDH1A1TSHR | |
| SCHEMBL23013538 | 1.00 | CTSK (0.51) | CTSKCTSSTDP1ALDH1A1TSHR | |
| SCHEMBL4711467 | 0.95 | CTSK (0.52) | CTSKCTSSTDP1ALDH1A1TSHR | |
| SCHEMBL5285944 | 0.95 | CTSK (0.52) | CTSKCTSSTDP1ALDH1A1TSHR | |
| SCHEMBL4024795 | 0.95 | CTSK (0.52) | CTSKCTSSTDP1ALDH1A1TSHR | |
| SCHEMBL6745774 | 0.93 | CTSK (0.56) | CTSKCTSSALDH1A1TSHRMEN1 | |
| SCHEMBL14150791 | 0.93 | CTSK (0.56) | CTSKCTSSALDH1A1TSHRMEN1 | |
| SCHEMBL6837916 | 0.90 | CTSK (0.56) | CTSKCTSSALDH1A1TSHRMEN1 | |
| Myristyl Alcohol SCHEMBL28942416 | 0.90 | CTSK (0.59) | CTSKCTSSTDP1 | |
| SCHEMBL2781378 | 0.88 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| US-6335443-B1 | Chemical synthesis of exochelins | KEYSTONE BIOMEDICAL, INC. | 2002-01-01 | — | — | US | claimed |
| EP-1105416-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | Keystone Biomedical, Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| EP-1105415-A1 | CHEMICAL SYNTHESIS OF EXOCHELINS | Keystone Biomedical, Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| US-6063919-A | ESTERIFICATION OF O-DEPROTECTED DIBENZYL EXOCHELIC ACID WITH BENZYL EPI-COBACTIN, HYDROGENOLYTICALLY REMOVING THE THREE BENZYL GROUPS TO FORM EXOCHELIN 786SM(R) | KEYSTONE BIOMEDICAL, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-2000009548-A1 | CHEMICAL SYNTHESIS OF EXOCHELINS | KEYSTONE BIOMEDICAL, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| WO-2000009547-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | KEYSTONE BIOMEDICAL, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| US-5952492-A | REACTING A MIXTURE OF DIACID WITH DIMETHYL PIMELATE, HYDROCHLORIC ACID, METHANOL, DIBUTYL ETHER TO FORM INTERMEDIATE, ADDING O-BENZYL HYDROXYLAMINE HYDROCHLORIDE AND TRIETHYLAMINE, ADDITING DI-TERT-BUTYL DICARBONATE | KEYSTONE BIOMEDICAL, INC. (US) | 1999-09-14 | — | — | US | claimed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240270704-A1 | AMINO ACIDS BEARING A TETRAZINE MOIETY | VALANX BIOTECH GMBH (AT) | 2024-08-15 | — | — | US | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| EP-4347572-A1 | AMINO ACIDS BEARING A TETRAZINE MOIETY | VALANX Biotech GmbH (AT) | 2024-04-10 | — | — | EP | disclosed |
| US-6063919-A | ESTERIFICATION OF O-DEPROTECTED DIBENZYL EXOCHELIC ACID WITH BENZYL EPI-COBACTIN, HYDROGENOLYTICALLY REMOVING THE THREE BENZYL GROUPS TO FORM EXOCHELIN 786SM(R) | KEYSTONE BIOMEDICAL, INC. (US) | 2000-05-16 | — | — | US | disclosed |
| US-6063919-A | ESTERIFICATION OF O-DEPROTECTED DIBENZYL EXOCHELIC ACID WITH BENZYL EPI-COBACTIN, HYDROGENOLYTICALLY REMOVING THE THREE BENZYL GROUPS TO FORM EXOCHELIN 786SM(R) | KEYSTONE BIOMEDICAL, INC. (US) | 2000-05-16 | — | — | US | disclosed |
| WO-2000009548-A1 | CHEMICAL SYNTHESIS OF EXOCHELINS | KEYSTONE BIOMEDICAL, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009547-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | KEYSTONE BIOMEDICAL, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009547-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | KEYSTONE BIOMEDICAL, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| US-5952492-A | REACTING A MIXTURE OF DIACID WITH DIMETHYL PIMELATE, HYDROCHLORIC ACID, METHANOL, DIBUTYL ETHER TO FORM INTERMEDIATE, ADDING O-BENZYL HYDROXYLAMINE HYDROCHLORIDE AND TRIETHYLAMINE, ADDITING DI-TERT-BUTYL DICARBONATE | KEYSTONE BIOMEDICAL, INC. (US) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | CTSK 1101/4885CTSS 640/4885TDP1 2070/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | CTSK 1467/4885CTSS 1044/4885TDP1 4285/4885 |
| US-20240270704-A1 | AMINO ACIDS BEARING A TETRAZINE MOIETY | DNPEP, ANPEP, BCAT1 | CTSK 2539/4885CTSS 3253/4885TDP1 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.